Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
|Slideshows|July 26, 2018
Inflammation and Response to ECT in Treatment-Resistant Depression
Author(s)Brian Miller, MD, PhD, MPH
ECT is a highly effective treatment for depression, but a portion of patients fail to respond as hoped. Clinical variables have overall limited utility as a predictor of response. Is inflammation the key?
Advertisement
Advertisement
Related to this article
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
2
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
3
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
4
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
5